Literature DB >> 30924019

Long-Term Outcomes After Surgical Resection for Pleural Dissemination of Thymoma.

Kenji Kimura1, Ryu Kanzaki2, Toru Kimura3, Takashi Kanou1, Naoko Ose1, Soichiro Funaki1, Masato Minami1, Yasushi Shintani1, Meinoshin Okumura1,4.   

Abstract

BACKGROUND: Cases of thymoma with pleural dissemination are occasionally encountered, and their management is difficult. Some reports have noted that surgical treatment for dissemination is effective, although the long-term results and clinical course details remain unclear. The current study investigated the short- and long-term outcomes of surgical resection of pleural dissemination.
METHODS: A retrospective review examined the medical records for 38 patients who underwent surgical resection for pleural dissemination occurring synchronously with a primary thymoma or metachronously after complete surgical resection of a primary thymoma between 1996 and 2017 at the authors' institution. Clinical characteristics and prognostic factors were analyzed.
RESULTS: The patients were classified into synchronous (n = 21) and metachronous (n = 17) groups. The 10-year overall survival rate was 59% for the synchronous group and 88% for the metachronous group. The median follow-up period for all the patients was 61 months (range 4-225 months). No perioperative deaths occurred. For all the patients, the 5- and 10-year overall survival rates were respectively 91% and 82%, and the 5- and 10-year relapse-free survival rates were respectively 29% and 19%. A significantly worse prognosis was observed for patients 50 years of age or older than for those younger than 50 years (p = 0.02). For 13 patients who underwent repeat resection for pleural dissemination, the prognosis was better than for those without repeat resection (p < 0.01).
CONCLUSION: Surgical resection of thymoma with pleural disseminated nodules can be safely performed and provides a favorable long-term outcome. Repeat resection is considered to be effective for achieving a good prognosis.

Entities:  

Mesh:

Year:  2019        PMID: 30924019     DOI: 10.1245/s10434-019-07330-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Surgical management of thymic epithelial tumors.

Authors:  Yasushi Shintani; Soichiro Funaki; Naoko Ose; Takashi Kanou; Eriko Fukui; Kenji Kimura; Masato Minami
Journal:  Surg Today       Date:  2020-07-10       Impact factor: 2.549

2.  Tubeless video-assisted thoracoscopic surgery in mediastinal tumor resection.

Authors:  Weixue Cui; Danxia Huang; Hengrui Liang; Guilin Peng; Mengyang Liu; Run Li; Xin Xu; Jianxing He
Journal:  Gland Surg       Date:  2021-04

3.  Spontaneous ventilation video-assisted thoracic surgery for mediastinal tumor resection in patients with pulmonary function deficiency.

Authors:  Weizhe Huang; Hongsheng Deng; Yuting Lan; Runchen Wang; Fan Ge; Zhenyu Huo; Yi Lu; Weiyi Lin; Guo Lin; Wenhua Liang; Hengrui Liang; Jianxing He
Journal:  Ann Transl Med       Date:  2020-11

4.  Pathological tumor long-to-short axis ratio as a prognostic factor in patients with thymic epithelial tumors.

Authors:  Dong Tian; Haruhiko Shiiya; Masaaki Sato; Aya Shinozaki-Ushiku; Hao-Ji Yan; Jun Nakajima
Journal:  Thorac Cancer       Date:  2022-07-21       Impact factor: 3.223

5.  Local radiotherapy for pleural dissemination of thymic tumors after initial treatment.

Authors:  Dai Okazaki; Yuta Shibamoto; Takeshi Yanagi; Satoshi Ishikura; Takuhito Kondo; Yuki Yamada; Masanari Niwa
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

Review 6.  The role of surgery in the management of locally advanced and metastatic thymoma: a narrative review.

Authors:  Catherine Wagner; Elliot Wakeam; Shaf Keshavjee
Journal:  Mediastinum       Date:  2021-06-25

7.  Elevated serum CYFRA 21-1 level as a diagnostic marker for thymic carcinoma.

Authors:  Haruhiko Shiiya; Hideki Ujiie; Yasuhiro Hida; Tatsuya Kato; Kichizo Kaga; Satoru Wakasa; Eiki Kikuchi; Naofumi Shinagawa; Kazufumi Okada; Yoichi M Ito; Yoshihiro Matsuno
Journal:  Thorac Cancer       Date:  2021-09-27       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.